Last reviewed · How we verify

NCT03516136

Safety and Performance of the EndoFast Reliant SCP in Vaginal Wall Reinforcement

Completed Last updated 17 May 2018
What this trial tests

trial testing EndoFast Reliant SCP in Pelvic Organ Prolapse in 84 participants. Completed in 31 December 2017.

Timeline
1 January 2015
Primary endpoint
31 December 2017
31 December 2017

Quick facts

Lead sponsorAllium, Ltd.
StatusCompleted
Study typeOBSERVATIONAL
Enrollment84
Start date1 January 2015
Primary completion31 December 2017
Estimated completion31 December 2017

Drugs / interventions tested

Conditions studied

Sponsor

Allium, Ltd.

Who can join

18 and older, female only, with Pelvic Organ Prolapse. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Single arm, single site, retrospective cohort Post Marketing Clinical Follow up Study Evaluating the Safety and Performance of the EndoFast Reliant SCP for apical support.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pelvic Organ Prolapse

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03516136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing